ERBB2 and gastric cancer: In detail, 6 cases were HER2 amplified in the primary GC and not amplified in the metastases (negative conversion) (Figure 1), while 4 of the discordant cases were HER2 not amplified in the primitive tumour and amplified in the lymph node metastases (positive conversion) (Table 3) (Figure 2).